key: cord-0964604-8sj023uy authors: Avallone, Gianluca; Quaglino, Pietro; Cavallo, Francesco; Roccuzzo, Gabriele; Ribero, Simone; Zalaudek, Iris; Conforti, Claudio title: SARS‐CoV‐2 vaccine‐related cutaneous manifestations: a systematic review date: 2022-02-09 journal: Int J Dermatol DOI: 10.1111/ijd.16063 sha: 89d5eeed8e3c076ea590cb2e80f1d5f35b9ab3c0 doc_id: 964604 cord_uid: 8sj023uy To date, over 250 million people have been reportedly infected by COVID‐19 disease, which has spread across the globe and led to approximately 5.1 million fatalities. To prevent both COVID‐19 and viral transmission, DNA‐based/RNA‐based vaccines, non‐replicating viral vector vaccines, and inactivated vaccines have been recently developed. However, a precise clinical and histological characterization of SARS‐CoV‐2 vaccine‐related dermatological manifestations is still lacking. A systematic review of 229 articles was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, in order to provide an extensive overview of SARS‐CoV‐2 vaccine‐related skin manifestations. Data on demographics, number of reported cases with cutaneous involvement, vaccine, and rash type (morphology) were extracted from articles and summarized. A total of 5941 SARS‐CoV‐2 vaccine‐related dermatological manifestations were gathered. Local injection‐site reactions were the most frequently observed, followed by rash/unspecified cutaneous eruption, urticarial rashes, angioedema, herpes zoster, morbilliform/maculopapular/erythematous macular eruption, pityriasis rosea and pityriasis rosea‐like eruptions, and other less common dermatological manifestations. Flares of pre‐existing dermatological conditions were also reported. Cutaneous adverse reactions following SARS‐CoV‐2 vaccine administration seem to be heterogeneous, rather infrequent, and not life‐threatening. Vaccinated patients should be monitored for skin manifestations, and dermatological evaluation should be offered, when needed. To date, over 250 million people have been reportedly infected by COVID-19 disease, which has spread across the globe, leading to approximately 5.1 million fatalities. 1 Table 1 . Herein we provide a comprehensive overview of the most frequently observed skin-related manifestation following SARS-CoV-2 vaccine administration ( Table 1 , Fig. 2 ) and describe the potential mechanisms underlying their development. A clinicopathological study of a delayed-type hypersensitivity reaction following Moderna vaccine revealed as main features focal epidermal changes with epidermal spongiosis and exocytosis of a few lymphocytes as well as a perivascular and occasionally sleeve-like inflammatory infiltrate predominantly composed of small lymphocytes with an admixture of a variable number of eosinophilic granulocytes in the dermis. 84 Whether local injection-site manifestation corresponds to a hypersensitivity reaction to the spike protein or to different components of the vaccine is still unclear. As far as it and AstraZeneca vaccine (n = 8). Eleven cases were also associated with an unspecified COVID-19 vaccine. Delayed inflammatory reaction to dermal hyaluronic acid filler Among SARS-CoV-2 vaccine-related dermatological manifestations, COVID-19 vaccination seems to be a trigger of hyaluronic acid filler-associated delayed inflammatory reaction (DIR). A total of 23 patients have been gathered, showing DIR more frequently after the Moderna vaccine (n = 16) than the BNT162B2 vaccine (n = 6). Another case occurred after the administration of a not-specified COVID-19 vaccine. 192 McMahon et al. 138 Overall, skin involvement following SARS-CoV-2 vaccine administration showed to be more likely to be experienced by female patients (n = 1708) compared to male patients (n = 379) (ratio 4.5:1). However in few studies, such as the ones by Kadali et al. 34 and Riad et al. 233 , patients' gender could not be identified from the data provided, yet the overall self-reporting response by female patients was significantly higher in both studies (i.e. 88.5% 233 and 89.35% respectively 34 ). These data seem particularly true for local injection-site reactions, which have been reported more commonly in women. The possibility of sampling bias might also be considered in interpreting our findings since the early vaccine doses were first administered to healthcare workers (HCWs), the majority of which are females. More specifically, women seem to account for 70% of the whole health and social care sector worldwide, according to Boniol et al. 242 Coherently, most of the cases included in our review, especially the ones collected from registry-based studies 138 WHO Coronavirus disease Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial A method for estimating the probability of adverse drug reactions Quality assessment tool for case series studies Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? Lichen planus arising after COVID-19 vaccination Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine COVID arm": a reaction to the Moderna vaccine COVID-19 "second wave" and vaccines: the dermatologists' perspective Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers Skin tests in urticaria/ angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine Pernio after COVID-19 Vaccination New-onset chilblains in close temporal association to mRNA-1273 vaccination Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance Acral chilblainlike lesions following inactivated SARS-CoV-2 vaccination Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination Chilblain lesions after COVID-19 mRNA vaccine Herpes zoster emergence following mRNA COVID-19 vaccine A flare of preexisting erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine CoronaVac COVID-19 vaccination: a case report BNT162b2 mRNA Covid-19 Vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2 Leukocytoclastic vasculitis flare following the COVID-19 vaccine Varicella-zoster virus reactivation after SARS-Cov2 BNT162b2 mRNA vaccination: report of five cases Covid-19 vaccineinduced radiation recall phenomenon Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, crosssectional study with detailed self-reported symptoms from healthcare workers Safety of new mRNA vaccines against COVID-19 in severely allergic patients Local skin reaction to the AZD1222 vaccine in a patient who survived COVID-19 Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination Delayed localized hypersensitivity reactions to the moderna COVID-19 vaccine: a case series Recurrent injectionsite reactions after incorrect subcutaneous administration of a COVID-19 vaccine Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine 20 Post-COVID-19 vaccinerelated shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media Widespread annular eruption after Ad26.COV2.S COVID-19 vaccine Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2 Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results Local reactions to the second dose of the BNT162 COVID-19 vaccine SARS-CoV-2 mRNA vaccine-associated fixed drug eruption Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle? A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine Immune thrombocytopenic purpura associated with COVID-19 Pfizer-BioNTech BNT16B2b2 mRNA vaccine Radiation recall dermatitis triggered by inactivated COVID-19 vaccine COVID-19 vaccine-induced Stevens-Johnson syndrome Incidence and characteristics of delayed injection site reaction to the mRNA-1273 SARS-CoV2 vaccine (Moderna) in a cohort of hospital employees Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients Pityriasis rosea after mRNA COVID-19 vaccination Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance Localized cutaneous reaction to an mRNA COVID-19 vaccine Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2 Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine Skin rashes after SARS-CoV-2 vaccine: which relationship, if any? COVID Toes" after mRNA COVID-19 vaccines Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: is it an 'AstraZeneca arm'? Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infectionassociated cutaneous manifestations The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2 Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoid Primary cutaneous anaplastic large-cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination Delayed cutaneous reactivity associated with COVID-19 vaccines is rare Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence? Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature New-onset cutaneous lichen planus triggered by COVID-19 vaccination Widespread purpura annularis telangiectodes following mRNA SARS-CoV-2 vaccine Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination Pityriasis rosea developing after COVID-19 vaccination Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine COVID arm' -histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-1273 SARS-CoV2 vaccine New-onset leukocytoclastic vasculitis after COVID-19 vaccine Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination Eruption ecz ematiforme apr es le vaccin par Pfizer-BioNTech COVID-19 [Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vectorbased SARS-CoV-2 vaccination Delayed localized hypersensitivity reactions to COVID-19 mRNA vaccines: a 6-month retrospective study Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination Unique case of urticarial skin eruptions after COVID-19 vaccination Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: case report Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series Herpes Zoster following SARS-CoV-2 vaccination -a series of four cases New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report Small vessel vasculitis related to varicella-zoster virus after Pfizer-BioNTech COVID-19 vaccine A skin reaction with rust-like discolouration to mRNA COVID-19 vaccine New-onset acral lesions on hands after administration of mRNA-1273 vaccine against SARS-CoV-2: clinical images and histopathological study of three cases Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2 Acute encephalitis, myoclonus and sweet syndrome after mRNA-1273 vaccine Pityriasis rubra pilaris after Vaxzevriaâ COVID-19 vaccine Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): report of two cases Association of facial pustular neutrophilic eruption with messenger RNA-1273 SARS-CoV-2 vaccine Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature Skin necrosis at both COVID-19 vaccine injection sites Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre Type I interferon signature in chilblains following SARS-CoV-2 mRNA vaccine: a case report COVID-19 vaccine-induced urticarial vasculitis Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination Pityriasis rubra pilarislike eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac â ) in healthcare workers De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine Flagellate purpura associated with COVID-19 vaccination Cutaneous skin manifestation following messenger RNA Moderna SARS-CoV-2 vaccine with dermal hypersensitivity reaction histopathology An old entity, a new trigger: post COVID-19 vaccine pityriasis rubra pilaris Two cases of papulopustular rosacea-like eruptions following COVID-19 vaccinations A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology COVID vaccine arm' may present after both mRNA vaccines vaccination Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases Lichen striatus post-COVID-19 vaccination Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine Thrombosis of the palmar digital vein after Oxford-AstraZeneca COVID-19 vaccination Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine Cutaneous hypersensitivity reaction with acute hepatitis following COVID-19 vaccine Cutaneous adverse effects and contraindications to COVID-19 vaccination; four cases and an illustrative review from an Asian country Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry Oxford-AstraZeneca COVID-19 vaccineinduced acute localized exanthematous pustulosis Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine-A report of 3 cases Cutaneous small-vessel vasculitis following COVID-19 vaccine Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine Toxic Epidermal Necrolysis Post COVID-19 Vaccination -First Reported Case Early atypical injectionsite reactions to COVID-19 vaccine: a case series Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant) Pfizer-BioNTech SARS-CoV-2 mRNA vaccine-associated erythema multiforme COVID vaccineinduced lichen planus on areas previously affected by vitiligo SARS-CoV-2 mRNA vaccine injection site pseudolymphoma Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin? Nevocentric erythema multiforme after SARS-COV-2 vaccine Case report: pityriasis rosea-like eruption following COVID-19 vaccination Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series Disseminated varicellazoster virus infections following messenger RNA-based COVID-19 vaccination Atypical pityriasis rosea associated with mRNA COVID-19 vaccine A case of COVID-19 vaccination-associated forme fruste purpura fulminans Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female Viral-like reaction or hypersensitivity? Erythema multiforme minor reaction and moderate eosinophilia after receiving Pfizer-BioNTech BNT162b2 (mRNA-based SARS-CoV-2 vaccine) New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination Eruptive angiomatosis after SARS-CoV-2 vaccine (Comirnaty, Pfizer) Development of oral lichen planus after COVID-19 vaccination -a rare case report Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination Erythema nodosum, after Medigen vaccination against COVID-19? Generalized dermal hypersensitivity reaction following Moderna COVID-19 vaccination Sinovac COVID-19 vaccine-induced cutaneous leukocytoclastic vasculitis Regression of common viral warts after ChAdOx1-S COVID-19 vaccine Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Herpes simplex, herpes zoster and periorbital erythema flares after SARS-CoV-2 vaccination: 4 cases Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech) Raynaud's Phenomenon after COVID-19 vaccination: causative association, temporal connection, or mere bystander? Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines Systemic drug-related intertriginous and flexural exanthema (SDRIFE) induced by the Comirnaty Pfizer-BioNTech COVID-19 vaccine: a report of 2 cases Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80 Erythema migrans-like rash after Moderna vaccine: an uncommon type of "COVID arm Cutaneous reaction reported after third Moderna COVID-19 vaccine Delayed Skin Rash After Receiving SARS-CoV-2 mRNA Moderna Vaccine COVID-19 vaccinationinduced rash: does the choice of vaccine matter? A case of reactivation of varicellazoster virus after BNT162b2 vaccine second dose? Purpuric skin rash in a patient undergoing Pfizer-BioNTech COVID-19 vaccination: histological evaluation and perspectives Moderna COVID-19 vaccine induced skin rash Two cases of mild systemic adverse skin eruption after coronavirus disease 2019 vaccination A Rare Case of Henoch-Sch€ onlein Purpura Following a COVID-19 Vaccine-Case Report Petechiae and Desquamation of Fingers Following Immunization With BTN162b2 Messenger RNA (mRNA) COVID-19 Vaccine Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: an observational study Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination Herpes zoster after COVID vaccination Henoch-Sch€ onlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: a case report Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? Delayed large local reactions to mRNA Covid-19 vaccines in blacks, indigenous persons, and people of color Lichenoid cutaneous skin eruption and associated systemic inflammatory response following Pfizer-BioNTech mRNA COVID-19 vaccine administration Delayed cutaneous hypersensitivity reaction to Vaxzevria (ChAdOx1-S) vaccine against SARS-CoV-2 De novo guttate psoriasis following coronavirus disease 2019 vaccination COVID arm after moderna booster in healthcare worker: a case report Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States Erythema Multiforme Major following SARS-CoV-2 vaccine Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from The Philippines Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination -A case report Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: case report and brief literature review Post-vaccination COVID Toes (Chilblains) exacerbated by rituximab infusion suggests interferon activation as mechanism Side effects of mRNAbased COVID-19 vaccine: nationwide phase IV study among healthcare workers in slovakia Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: a case report Side effects of mRNAbased COVID-19 vaccines among young adults (18-30 Years Old): an independent post-marketing study Rare cutaneous manifestation of COVID-19 infection and Pfizer-BioNTech COVID-19 vaccine with a unique pattern similarity Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine A case of immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination Five Japanese cases of delayed large local reactions to coronavirus disease 2019 vaccines Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination Case of bullous pemphigoid following coronavirus disease 2019 vaccination Herpes zoster viral infection after AZD1222 and BNT162b2 coronavirus disease 2019 mRNA vaccines: a case series Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination Annular plaques mimicking Rowell's syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon? Erythema annulare centrifugum induced by SARS-CoV-2 vaccination Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V) Palms and soles itchiness as a side effect of COVID-19 vaccination Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine Safety and Reactogenicity of the ChAdOx1 (AZD1222) Vaccine in Saudi Arabia Herpes Zoster Following COVID-19 Vaccination Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19 Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines Herpes zoster after inactivated COVID-19 vaccine: a cutaneous adverse effect of the vaccine Prevalence of COVID-19 vaccine side effects among Healthcare Workers in The Czech Republic Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from North-East Italy Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? COVID toes: where do we stand with the current evidence? COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses Reactivation of herpesvirus infections after vaccinations? Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them? Gender Equity in the Health Workforce: Analysis of 104 Countries. Health Workforce Working Paper 1. Geneva: World Health Organization the International Society of Dermatology